Option chain shows key data for Atea Pharmaceuticals's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Atea Pharmaceuticals.

Atea Pharmaceuticals (NASDAQ:AVIR) Stock, Option Chain

Atea Pharmaceuticals

Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).

AVIR

Biotech

News

Health Care

Movers

Trading Ideas

General

Atea Pharmaceuticals reports 98% SVR12 in a Phase 2 hepatitis C study, supporting an eight-week treatment plan with bemnifosbuvir and ruzasvir.

After Failed COVID-19 Drug Trial, Atea Pharmaceuticals Touts Encouraging Data From Mid-Stage Hepatitis C Study

Earnings

Earnings Beats

Large Cap

Mid Cap

Penny Stocks

Small Cap

Markets

Analyst Ratings

RDNT

TMDX

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) is scheduled to report third-quarter 2024 results on Oct. 30, before market open.

ZBH Gears Up for Q3 Earnings: What Lies Ahead for the Stock?

Atea Pharmaceuticals&#39; Phase 3 SUNRISE-3 trial for bemnifosbuvir in COVID-19 patients did not meet the primary endpoint. The company remains focused on its hepatitis C combination therapy.

Atea Pharmaceuticals&#39; COVID-19 Treatment Flunks In Late-Stage Study, Blames &#39;Constantly Evolving&#39; Virus

Atea Pharmaceuticals, Inc. - common stock

Atea Pharmaceuticals Inc

SkyBridge Capital founder Anthony Scaramucci has described Bitcoin's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) current price action as part of its typical cycle.
What Happened: In an <a href="https://x.com/Scaramucci/status/1870118849959399556">X</a> post on Friday, he explained that Bitcoin is purging leveraged, short-term momentum trades, a normal phenomenon in its market evolution.
However, Scaramucci also suggested that some altcoins may have experienced their "last hurrah" and could be done for good.
Meanwhile, crypto entrepreneur JC X <a href="https://x.com/Scaramucci/status/1870118849959399556">believes</a> human behaviour remains consistent: when Bitcoin surges, investors feel wealthier and take on more risks, often chasing gains in altcoins due to FOMO. This dynamic suggests altcoins may still have another rally in store.
In an interview, <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42491094/anthony-scaramucci-upgrades-his-lamborghinibut-not-at-the-cost-of-selling-bitcoin-why-would-i-sell">Scaramucci expressed optimism</a> about Bitcoin&#8217;s future, stating he would never sell his holdings for luxury purchases. He emphasized Bitcoin's potential to attract <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42378636/scaramucci-bitcoin-is-a-volatile-asset-but-ready-for-prime-time-institutional-investing">mainstream institutional investment.</a>
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42617815/are-microstrategys-bitcoin-purchases-on-hold-in-january">Are MicroStrategy&#8217;s Bitcoin Purchases On Hold In January?</a>
Why It Matters: Cathie Wood of ARK Invest remains bullish on Bitcoin, projecting a price of $1.5 million by 2030, citing its <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42609380/cathie-wood-says-bitcoin-is-more-scarce-than-gold-predicts-ma-surge-under-trump-2-0">scarcity compared to gold</a>. 
A 10x Research report highlighted macroeconomic challenges, including the Federal Reserve's hawkish stance, <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42612972/bitcoins-2025-outlook-suddenly-looks-uncertain-heres-why">signaling a cautious year ahead</a> for traders and investors.
An expert from Foresight Ventures noted that Bitcoin's recent pullback marks its first significant correction since post-election euphoria. 
The analyst stated that <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42614273/bitcoin-crashes-10-ethereum-xrp-down-18-dogecoin-craters-28-what-is-going-on">20% corrections are typical</a> in bull markets, serving as consolidations rather than trend reversals.
Read Next: &nbsp;&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42613106/have-risk-appetite-here-are-5-cryptos-that-could-make-your-christmas-merry">Have Risk Appetite? Here Are 5 Cryptos That Could Make Your Christmas Merry</a></li>
</ul>
Photo: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

Anthony Scaramucci: Bitcoin's Moves Are 'Normal,' But Some Altcoins May Have Had Their 'Last Hurrah'

WIIM

Rumble shares are trading higher after the company announced it has entered into a definitive agreement for a strategic investment of $775 million from Tether.

Adrian Alexandru, representing all similarly affected investors, has filed a federal securities class-action lawsuit against Applied Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLT#NASDAQ">APLT</a>), alleging the company violated <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40921732/applied-therapeutics-stock-soars-as-fda-scraps-panel-meeting-for-its-inherited-metabolic-disorder" rel="noreferrer noopener">federal securities laws</a>.
The lawsuit claims that the company provided misleading information about its clinical trials and failed to disclose key adverse facts, causing significant financial losses for shareholders.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/40078613/rare-disease-focused-applied-therapeutics-lead-candidate-govorestat-has-blockbuster" rel="noreferrer noopener">Rare Disease-Focused Applied Therapeutics' Lead Candidate Govorestat Has Blockbuster Potential, Analyst Sees 140% Stock Upside</a>
The class action covers investors who purchased Applied Therapeutics securities between January 3, 2024, and December 2, 2024.
Central to the lawsuit are claims that the company touted positive results from its Phase 3 INSPIRE trial for govorestat for Galactosemia, without <a target="_blank" href="https://www.benzinga.com/24/11/42241059/regulatory-setback-for-applied-therapeutics-lead-program-fda-highlights-deficiencies-in-clinical-application" rel="noreferrer noopener">disclosing significant issues</a>. Bloomberg Law published a copy of the lawsuit online.
Allegations <a target="_blank" href="https://www.bloomberglaw.com/public/desktop/document/AlexandruetalvAppliedTherapeuticsIncetalDocketNo124cv09715SDNYDec?doc_id=X6AM5BLRTI48QBRMPF9SKEGPKV0" rel="noreferrer noopener">include</a> problems with electronic data capture and dosing errors during the dose-escalation phase of the study, which were concealed from investors.
Investor confidence began to erode on November 27, 2024, when Applied Therapeutics received an FDA Complete Response Letter (CRL).
The CRL indicated that the agency could not approve the company's New Drug Application for govorestat in its current form, citing deficiencies in the clinical application.
Following the disclosure, Applied Therapeutics' stock price dropped sharply, which worsened after the company <a target="_blank" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001697532/000095017024132306/aplt-20241202.htm" rel="noreferrer noopener">disclosed</a> receiving a warning letter from the FDA on December 2 highlighting unresolved clinical trial issues.
The FDA's warning letter pointed to electronic data capture problems and a dosing error that resulted in lower-than-targeted doses for some patients during the trial's early phase.
While Applied Therapeutics claims to have addressed these issues through detailed records and prior communications with the agency, investors reacted negatively to the revelations, further eroding the stock's value.
The lawsuit seeks to recover damages for investors who purchased shares at artificially inflated prices, alleging that the company's failure to provide accurate and complete information misled the market.
On Friday, Applied Therapeutics named John Johnson as executive chairman and announced that Shoshana Shendelman has stepped down as Chair and CEO. The company named Les Funtleyder, Applied Therapeutics' CFO, <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/g42613049/applied-therapeutics-appoints-john-h-johnson-as-executive-chairman" rel="noreferrer noopener">as the interim CEO</a>.
RBC Capital analyst maintains Applied Therapeutics with a Sector Perform, lowering the price target from $4 to $1.5.
Price Action: APLT stock closed lower by 13.7% to $0.87 on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42614476/whats-going-on-with-kroger-stock-after-revealing-5-billion-buyback" target="_blank" rel="noreferrer noopener">Kroger Launches $5 Billion Accelerated Share Repurchase: Details</a></li>
</ul>

Legal

APLT

Penny Stock Applied Therapeutics' FDA Troubles Trigger Investor Lawsuit, Shareholders Claim Deception Over Govorestat Clinical Data

Comfort Systems USA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIX#NYSE">FIX</a>) has outperformed the market over the past 10 years by 27.08% on an annualized basis producing an average annual return of 38.07%. Currently, Comfort Systems USA has a market capitalization of $15.61 billion. 
Buying $100 In FIX: If an investor had bought $100 of FIX stock 10 years ago, it would be worth $2,552.04 today based on a price of $438.44 for FIX at the time of writing.
<h3>Comfort Systems USA's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734732908_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In Comfort Systems USA 10 Years Ago Would Be Worth Today

Stran &amp; Company, Inc. ("Stran" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWAG#NASDAQ">SWAG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWAGW#NASDAQ">SWAGW</a>), a leading outsourced marketing solutions provider that leverages its promotional products and loyalty incentive expertise, today announced that on December 17, 2024, it received a letter from the Listing Qualifications staff (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq"), issuing a Staff delisting determination (the "Staff Determination"). The Staff Determination noted that the Staff had notified the Company on June 21, 2024, August 23, 2024 and November 21, 2024 that the Company did not comply with Nasdaq Listing Rule 5250(c)(1) (the "Filing Rule") because the Company had not filed its Quarterly Reports on Form 10-Q for the periods ended March 31, 2024, June 30, 2024, and September 30, 2024 (the "Forms 10-Q") with the Securities and Exchange Commission (the "SEC"). The Staff Determination noted that, based on the Staff's review and the materials submitted on August 20, 2024, the Staff granted the Company an exception until December 16, 2024 to regain compliance with the Filing Rule. The Staff Determination stated that the Company had not met the terms of the exception. Specifically, the Company has not filed the Forms 10-Q as required by the Filing Rule. The Staff Determination has no immediate effect and will not immediately result in the suspension of trading or delisting of the Company's common stock.

SWAG

SWAGW

Stran & Company Receives Nasdaq Staff Delisting Determination

Jiayin Group Inc. ("Jiayin" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JFIN#NASDAQ">JFIN</a>), a leading fintech platform in China, today announced that it entered into a definitive agreement on December 17, 2024 to purchase certain commercial property located in Shanghai, China (the "Commercial Property") of approximately 43,500 square meters for total cash consideration of approximately RMB1.35 billion. The completion of the purchase is subject to customary closing conditions. The Commercial Property will primarily be used as the Company's new headquarters to meet the demand arising from the continuing growth of the Company's businesses.

JFIN

Jiayin Group Announces Purchase Of Commercial Property Located In Shanghai, China For Total Cash Consideration Of ~RMB1.35 Billion

Taiwan Semiconductor Manufacturing Co&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) <a target="_blank" href="https://www.benzinga.com/government/24/08/40554768/taiwan-semiconductor-ramps-up-overseas-investments-with-1-95b-in-subsidies-eyes-long-term-growth" rel="noreferrer noopener">debut plant in</a> Kumamoto, Japan, will start commercializing by the end of 2024.
Sony Group Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SONY#NYSE">SONY</a>) and Denso Corp (OTC:<a class="ticker" href="https://www.benzinga.com/stock/DNZOF#OTC">DNZOF</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/DNZOY#OTC">DNZOY</a>) will be the Taiwanese contract chipmaker&#8217;s initial customers, Technode <a target="_blank" href="https://technode.com/2024/12/19/tsmcs-kumamoto-plant-to-supply-initial-output-to-sony-and-denso/" rel="noreferrer noopener">cited</a> JASM (Taiwan Semiconductor&#8217;s Japanese subsidiary) President Yuichi Horita from a Taiwanese media outlet.
Horita expects Taiwan Semiconductor&#8217;s production line in Japan to align with the quality of those in Taiwan.
The first Kumamoto plant focuses on 22 nm,28 nm, 12 nm, and 16nm processes, while the second will produce 6 nm and 7nm process chips, as planned.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/emerging-markets/24/12/42552200/sony-semiconductor-hits-20-billion-image-sensor-shipments-plans-expansion" rel="noreferrer noopener">Sony Semiconductor Hits 20 Billion Image Sensor Shipments, Plans Expansion</a>
Construction of the second Kumamoto plant will likely begin in the first quarter of 2025, with mass production scheduled by the end of 2027.
The combined monthly production capacity of the two plants will likely exceed 100,000 wafers.
The Japanese government <a target="_blank" href="https://www.benzinga.com/government/regulations/24/11/41939018/japan-increases-semiconductor-funding-as-us-trade-policies-pressure-taiwan-semiconductor" rel="noreferrer noopener">earmarked over $64.9 billion</a> to consolidate its semiconductor and artificial intelligence (AI) positions, taking a cue from the U.S. and China. Taiwan Semiconductor&#8217;s Arizona fab, worth $20 billion, will produce <a target="_blank" href="https://www.benzinga.com/media/24/12/42514266/taiwan-semiconductor-unveils-20-billion-arizona-chip-fab-apple-named-key-customer" rel="noreferrer noopener">4-nanometer chips by 2025</a>.
Currently, 92% of the most advanced chips are made in Taiwan.
Japan&#8217;s semiconductor package totals over 10 trillion yen and aims to drive public and private investment of over 50 trillion yen by fiscal 2030.
Taiwan Semiconductor is eyeing a second facility in Japan&#8217;s Kumamoto, following its initial $8.6 billion wafer factory in the region. The company plans to invest $13.5 billion in the project.
The chipmaker is also plotting a third high-tech chip production facility worth $20 billion in Kumamoto to manufacture 3 nm chips.
Taiwan Semiconductor chair and CEO&nbsp;C.C. Wei <a target="_blank" href="https://www.benzinga.com/24/12/42507816/taiwan-semiconductor-ceo-highlights-ai-powered-drones-next-gen-robots-as-growth-drivers" rel="noreferrer noopener">expects advanced robots</a> and AI-powered drones to be key growth drivers.
Taiwan Semiconductor stock surged 92% year-to-date.
Investors can gain exposure to the semiconductor sector through VanEck Semiconductor ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMH#NASDAQ">SMH</a>) and iShares Semiconductor ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOXX#NASDAQ">SOXX</a>).
Price Action: TSM stock closed higher by 1.32% to $197.21 on Friday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/media/24/12/42554393/disneys-marvel-rivals-game-hits-20-million-players-proves-superhero-power-still-reigns" target="_blank" rel="noreferrer noopener">Disney&#8217;s Marvel Rivals Game Hits 20 Million Players, Proves Superhero Power Still Reigns</a></li>
</ul>
Photo by Sundry Photography on Shutterstock

Tech

Media

DNZOF

DNZOY

Sony Group Corporation American Depositary Shares

SONY

iShares PHLX SOX Semiconductor Sector Index Fund

SOXX

Taiwan Semiconductor Expands in Japan: Sony and Denso Among First Customers

Procaps Group, S.A. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PROC#NASDAQ">PROC</a>) ("Procaps" or the "Company"), a leading integrated LatAm healthcare and pharmaceutical services company, today announced significant outcomes from its recent Shareholders Meeting and subsequent Board of Directors meeting. These include changes to the Board composition, restructuring of Board committees, and updates to its executive leadership team.
The Shareholders Meeting marked an important milestone with the election of new members to the Board of Directors. The newly elected members bring a diverse range of expertise and strategic insight to guide Procaps' future growth. Newly appointed Board members include:
<ul>
<li>Mr. Alejandro Weinstein, Executive Chairman of the board</li>
<li>Mr. Nicolas Weinstein</li>
<li>Mr. Ernesto Carrizosa</li>
<li>Mr. Jose Frugone</li>
</ul>
The company also acknowledges the resignation of Mr. David Yanovich from the Board of Directors. Procaps expresses its gratitude to Mr. Yanovich for his valuable contributions and dedication during his tenure.
The Board of Directors will be composed of Alejandro Weinstein, José Minski, Alberto Eguiguren, Nicolas Weinstein, Ernesto&nbsp;Carrizosa and Jose Frugone.

Management

PROC

Procaps Group Appoints Alejandro Weinstein, Executive Chairman Of The board

Exicure, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XCUR#NASDAQ">XCUR</a>, "the Company", "Exicure"))), today announced that in connection with the change of control transaction approved by the stockholders at the Special Meeting of the Stockholders on December 17, 2024 (the "Change of Control"), the stockholders of the Company approved a second investment of $8.7 million from HiTron Systems Inc. ("HiTron"), a publicly listed company (KOSPI) in South Korea. This investment is expected to close within a few days depending on regulatory approvals. Also, on December 19, 2024, the Board of Directors (the "Board") of the Company changed the authorized number of directors comprising the Board to nine directors and appointed four new directors to the Board and two officers to the Company.
The total investment from HiTron will be $10 million after the initial investment of $1.3 million closed in November. The share issuance price for HiTron is $3 per share per the common stock purchase agreement that was signed in early November, and once the second investments closes, HiTron will become Exicure's largest shareholder, owning over 50% of the Company. On December 17, 2024, HiTron completed the acquisition of Exicure's management rights through the appointment of board members.

Financing

Contracts

XCUR

Exicure Announces Shareholders Approve $8.7M Equity Financing From HiTron Systems

Strategic Investment Results in Mission-Aligned Investor and Supporter
Rumble Will Use $250 Million of Proceeds to Further Solidify Balance Sheet and Accelerate Growth Initiatives
Remaining Proceeds Will Be Used to Fund Self Tender Offer for up to 70 Million of Rumble's Class A Common Stock to Provide Liquidity to Stockholders at Same Price as Tether Investment
LONGBOAT KEY, Fla., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Rumble (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUM#NASDAQ">RUM</a>) ("Rumble" or the "Company"), the video-sharing platform and cloud services provider, announced today that it has entered into a definitive agreement for a strategic investment of $775 million from Tether ($USDT) ("Tether"), the largest company in the digital assets industry and the most widely used dollar stablecoin across the world with more than 350 million users. Over the last few years, Tether has become one of the most recognized symbols for financial inclusion.
The Company will use $250 million of the proceeds to support growth initiatives and the remaining proceeds to fund a self tender offer for up to 70 million of its Class A Common Stock, at the same price ($7.50 per share) as Tether's investment. Following the completion of the transaction, Chris Pavlovski, Rumble's Chairman and CEO, will retain his controlling stake in the Company.

$USDT

Rumble Announces $775M Strategic Investment From Tether;  Rumble CEO Retains Controlling Stake; Will Use $250M Of The Proceeds To Support Growth Initiatives And The Remaining Proceeds To Fund A Self Tender Offer For Up To 70M Of Its Class A Common Stock, Or $7.50 Per Share As Tether's Investment

Chart Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GTLS#NYSE">GTLS</a>) underwent analysis by 10 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $180.8, a high estimate of $210.00, and a low estimate of $145.00. This current average reflects an increase of 4.93% from the previous average price target of $172.30. 
<img src="https://www.benzinga.com/files/images/story/2024/1734732091_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
A clear picture of Chart Industries's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ati Modak</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$201.00</td>
<td>$138.00</td>
</tr>
<tr>
<td>Gregory Lewis</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$210.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Pavel Molchanov</td>
<td>Raymond James</td>
<td>Maintains</td>
<td>Strong Buy</td>
<td>$190.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Eric Stine</td>
<td>Craig-Hallum</td>
<td>Raises</td>
<td>Buy</td>
<td>$207.00</td>
<td>$199.00</td>
</tr>
<tr>
<td>Benjamin Nolan</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$200.00</td>
<td>$198.00</td>
</tr>
<tr>
<td>David Anderson</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$145.00</td>
<td>$146.00</td>
</tr>
<tr>
<td>David Anderson</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$146.00</td>
<td>$147.00</td>
</tr>
<tr>
<td>Chase Mulvehill</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$165.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Benjamin Nolan</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$198.00</td>
<td>$199.00</td>
</tr>
<tr>
<td>Roger Read</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$146.00</td>
<td>$151.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Chart Industries. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Chart Industries compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Chart Industries's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into Chart Industries's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/GTLS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Chart Industries analyst ratings.</a>
<h2>About Chart Industries</h2>
Chart Industries provides a variety of cryogenic equipment for storage, distribution, and other processes within the industrial gas and liquefied natural gas industries. It also provides natural gas processing solutions for the natural gas industry and specialty products that serve a variety of spaces, including hydrogen, biofuels, cannabis, and water treatment. The firm acquired Howden in a significant deal in early 2023, roughly doubling the size of the company.
<h3>Key Indicators: Chart Industries's Financial Health</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, Chart Industries showcased positive performance, achieving a revenue growth rate of 18.33% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Industrials sector.
Net Margin: Chart Industries's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 5.85%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Chart Industries's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 2.17%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Chart Industries's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 0.66%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 1.34, caution is advised due to increased financial risk.
<h2>What Are Analyst Ratings?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

GTLS

Analyst Expectations For Chart Industries's Future

Throughout the last three months, 15 analysts have evaluated Doximity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCS#NYSE">DOCS</a>), offering a diverse set of opinions from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">10</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $53.6, with a high estimate of $75.00 and a low estimate of $33.00. Marking an increase of 58.07%, the current average surpasses the previous average price target of $33.91. 
<img src="https://www.benzinga.com/files/images/story/2024/1734732084_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The standing of Doximity among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jeff Garro</td>
<td>Stephens &amp; Co.</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$55.00</td>
<td>-</td>
</tr>
<tr>
<td>Steven Valiquette</td>
<td>Mizuho</td>
<td>Announces</td>
<td>Neutral</td>
<td>$55.00</td>
<td>-</td>
</tr>
<tr>
<td>Anne Samuel</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$48.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>David Roman</td>
<td>Goldman Sachs</td>
<td>Announces</td>
<td>Neutral</td>
<td>$58.00</td>
<td>-</td>
</tr>
<tr>
<td>Jailendra Singh</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$49.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Ricky Goldwasser</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$53.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Richard Close</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Hold</td>
<td>$60.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Stephanie Davis</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$75.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Brian Peterson</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$65.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Stan Berenshteyn</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$41.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Scott Schoenhaus</td>
<td>Keybanc</td>
<td>Announces</td>
<td>Overweight</td>
<td>$70.00</td>
<td>-</td>
</tr>
<tr>
<td>Ricky Goldwasser</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Underweight</td>
<td>$33.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Stephanie Davis</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$52.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Elizabeth Anderson</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$45.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Allen Lutz</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$45.00</td>
<td>$32.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Doximity. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Doximity compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Doximity's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Capture valuable insights into Doximity's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/DOCS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Doximity analyst ratings.</a>
<h2>All You Need to Know About Doximity</h2>
Doximity Inc is a digital platform for U.S. medical professionals. Its cloud-based platform provides members with tools specifically built for medical professionals, enabling them to collaborate with their colleagues, securely coordinate patient care, conduct virtual patient visits, stay up-to-date with the latest medical news and research, and manage their careers.
<h3>Financial Insights: Doximity</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Growth: Doximity's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 20.44%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Doximity's net margin is impressive, surpassing industry averages. With a net margin of 32.27%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Doximity's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 4.71% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Doximity's ROA stands out, surpassing industry averages. With an impressive ROA of 4.03%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.01.
<h2>Analyst Ratings: Simplified</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

DOCS

Forecasting The Future: 15 Analyst Projections For Doximity

Throughout the last three months, 5 analysts have evaluated Rigetti Computing (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGTI#NASDAQ">RGTI</a>), offering a diverse set of opinions from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $4.8, along with a high estimate of $12.00 and a low estimate of $2.00. This current average has increased by 74.55% from the previous average price target of $2.75. 
<img src="https://www.benzinga.com/files/images/story/2024/1734732063_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Rigetti Computing. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Richard Shannon</td>
<td>Craig-Hallum</td>
<td>Announces</td>
<td>Buy</td>
<td>$12.00</td>
<td>-</td>
</tr>
<tr>
<td>Craig Ellis</td>
<td>B. Riley Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$4.00</td>
<td>$3.50</td>
</tr>
<tr>
<td>David Williams</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$2.50</td>
<td>$2.50</td>
</tr>
<tr>
<td>Craig Ellis</td>
<td>B. Riley Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$3.50</td>
<td>$3.00</td>
</tr>
<tr>
<td>Quinn Bolton</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$2.00</td>
<td>$2.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Rigetti Computing. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Rigetti Computing compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Rigetti Computing's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
For valuable insights into Rigetti Computing's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/RGTI/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Rigetti Computing analyst ratings.</a>
<h2>Unveiling the Story Behind Rigetti Computing</h2>
Rigetti Computing Inc is engaged in the business of full-stack quantum computing. Its proprietary quantum-classical infrastructure provides ultra-low latency integration with public and private clouds for high-performance practical quantum computing. The company has developed the industry's first multi-chip quantum processor for scalable quantum computing systems. Geographically, it derives a majority of its revenue from the United States.
<h3>Rigetti Computing: A Financial Overview</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Challenges: Rigetti Computing's revenue growth over 3 months faced difficulties. As of 30 September, 2024, the company experienced a decline of approximately -23.41%. This indicates a decrease in top-line earnings. When compared to others in the Information Technology sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Rigetti Computing's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -623.76%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Rigetti Computing's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -12.11%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Rigetti Computing's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -9.28%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Rigetti Computing's debt-to-equity ratio is below the industry average at 0.18, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: What Are They?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

RGTI

The Analyst Verdict: Rigetti Computing In The Eyes Of 5 Experts

Lumen Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUMN#NYSE">LUMN</a>) underwent analysis by 5 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $5.55, along with a high estimate of $8.00 and a low estimate of $4.25. Witnessing a positive shift, the current average has risen by 6.73% from the previous average price target of $5.20.
<img src="https://www.benzinga.com/files/images/story/2024/1734732051_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The analysis of recent analyst actions sheds light on the perception of Lumen Technologies by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bora Lee</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$4.25</td>
<td>$4.00</td>
</tr>
<tr>
<td>Michael Rollins</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$8.00</td>
<td>$6.50</td>
</tr>
<tr>
<td>Gregory Williams</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$6.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>James Schneider</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$5.00</td>
<td>$4.50</td>
</tr>
<tr>
<td>James Schneider</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$4.50</td>
<td>$4.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Lumen Technologies. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Lumen Technologies compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Lumen Technologies's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Lumen Technologies's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/LUMN/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Lumen Technologies analyst ratings.</a>
<h2>Discovering Lumen Technologies: A Closer Look</h2>
With 450,000 route miles of fiber, Lumen Technologies is one of the United States' largest telecommunications carriers serving global enterprises. Its merger with Level 3 in 2017 and divestiture of much of its incumbent local exchange carrier, or ILEC, business in 2022 has shifted the company's operations away from its legacy consumer business and toward enterprises (now about 75% of revenue). Lumen offers businesses a full menu of communications services, providing colocation and data center services, data transportation, and end-user phone and internet service. On the consumer side, Lumen provides broadband and phone service across 37 states, where it has 4.5 million broadband customers.
<h3>Lumen Technologies: Financial Performance Dissected</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Challenges: Lumen Technologies's revenue growth over 3 months faced difficulties. As of 30 September, 2024, the company experienced a decline of approximately -11.54%. This indicates a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Communication Services sector.
Net Margin: Lumen Technologies's net margin excels beyond industry benchmarks, reaching -4.59%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Lumen Technologies's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -36.63%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Lumen Technologies's ROA excels beyond industry benchmarks, reaching -0.44%. This signifies efficient management of assets and strong financial health.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 55.03, caution is advised due to increased financial risk.
<h2>Analyst Ratings: Simplified</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

LUMN

What 5 Analyst Ratings Have To Say About Lumen Technologies

Analysts' ratings for Marvell Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) over the last quarter vary from bullish to bearish, as provided by 26 analysts.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">10</td>
<td align="right">12</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">9</td>
<td align="right">12</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Marvell Tech and provided 12-month price targets. The average target is $118.88, accompanied by a high estimate of $140.00 and a low estimate of $91.00. This current average reflects an increase of 18.74% from the previous average price target of $100.12. 
<img src="https://www.benzinga.com/files/images/story/2024/1734732043_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Marvell Tech. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joseph Moore</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$120.00</td>
<td>$102.00</td>
</tr>
<tr>
<td>Toshiya Hari</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$115.00</td>
<td>$87.00</td>
</tr>
<tr>
<td>Harlan Sur</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$130.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Gary Mobley</td>
<td>Loop Capital</td>
<td>Raises</td>
<td>Hold</td>
<td>$110.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Atif Malik</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$112.00</td>
<td>$91.00</td>
</tr>
<tr>
<td>Matthew Prisco</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Overweight</td>
<td>$135.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>John Vinh</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$125.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Timothy Arcuri</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$115.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Christian Schwab</td>
<td>Craig-Hallum</td>
<td>Raises</td>
<td>Buy</td>
<td>$132.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Rick Schafer</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$125.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Harsh Kumar</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$120.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Christopher Rolland</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Positive</td>
<td>$125.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Tore Svanberg</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$125.00</td>
<td>$114.00</td>
</tr>
<tr>
<td>Joseph Moore</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$102.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Mark Lipacis</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$127.00</td>
<td>$122.00</td>
</tr>
<tr>
<td>Vivek Arya</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$125.00</td>
<td>$108.00</td>
</tr>
<tr>
<td>Hans Mosesmann</td>
<td>Rosenblatt</td>
<td>Raises</td>
<td>Buy</td>
<td>$140.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Cody Acree</td>
<td>Benchmark</td>
<td>Raises</td>
<td>Buy</td>
<td>$135.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Quinn Bolton</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$120.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Blayne Curtis</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$115.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Mark Lipacis</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$122.00</td>
<td>$98.00</td>
</tr>
<tr>
<td>Christopher Rolland</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Positive</td>
<td>$110.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Rick Schafer</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$110.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Aaron Rakers</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$110.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Gary Mobley</td>
<td>Loop Capital</td>
<td>Announces</td>
<td>Hold</td>
<td>$95.00</td>
<td>-</td>
</tr>
<tr>
<td>Atif Malik</td>
<td>Citigroup</td>
<td>Maintains</td>
<td>Buy</td>
<td>$91.00</td>
<td>$91.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Marvell Tech. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Marvell Tech compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Marvell Tech's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
For valuable insights into Marvell Tech's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/MRVL/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Marvell Tech analyst ratings.</a>
<h2>About Marvell Tech</h2>
Marvell Technology is a fabless chip designer focused on wired networking, where it has the second-highest market share. Marvell serves the data center, carrier, enterprise, automotive, and consumer end markets with processors, optical and copper transceivers, switches, and storage controllers.
<h3>Understanding the Numbers: Marvell Tech's Finances</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Over the 3 months period, Marvell Tech showcased positive performance, achieving a revenue growth rate of 6.87% as of 31 October, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Information Technology sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -44.61%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -4.9%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -3.38%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.32, Marvell Tech adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>How Are Analyst Ratings Determined?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

MRVL

Beyond The Numbers: 26 Analysts Discuss Marvell Tech Stock

Blue Owl Cap (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OWL#NYSE">OWL</a>) underwent analysis by 13 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">8</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $24.92, with a high estimate of $28.00 and a low estimate of $21.00. This upward trend is apparent, with the current average reflecting a 11.15% increase from the previous average price target of $22.42.
<img src="https://www.benzinga.com/files/images/story/2024/1734732034_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Blue Owl Cap. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kyle Voigt</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$26.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Michael Brown</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$25.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Chris Kotowski</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$28.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Brian McKenna</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$27.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Brian McKenna</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$27.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Brian Bedell</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Buy</td>
<td>$24.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Crispin Love</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$25.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Brennan Hawken</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$27.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Chris Kotowski</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$24.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Michael Brown</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$21.00</td>
<td>$18.50</td>
</tr>
<tr>
<td>Crispin Love</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$23.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Brian McKenna</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$25.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Glenn Schorr</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$22.00</td>
<td>$21.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Blue Owl Cap. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Blue Owl Cap compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Blue Owl Cap's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Blue Owl Cap's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/OWL/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Blue Owl Cap analyst ratings.</a>
<h2>Get to Know Blue Owl Cap Better</h2>
Blue Owl Capital Inc is an alternative asset management firm. The Company deploys private capital across Credit, GP Strategic Capital, and Real Estate platforms on behalf of institutional and private wealth clients. The Company conducts its operations through Blue Owl Capital Holdings LP ("Blue Owl Holdings") and Blue Owl Capital Carry LP ("Blue Owl Carry"). Its investor base includes a diversified mix of institutional investors, including public and private pension funds, endowments, foundations, family offices, private banks, high-net-worth individuals, asset managers, and insurance companies. The Company generates substantially all of its revenues in the United states.
<h3>Blue Owl Cap's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Positive Revenue Trend: Examining Blue Owl Cap's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 39.85% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Financials sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Blue Owl Cap's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 4.96%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Blue Owl Cap's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 1.59%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Blue Owl Cap's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 0.29%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Blue Owl Cap's debt-to-equity ratio surpasses industry norms, standing at 1.45. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>Analyst Ratings: Simplified</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Analyst Verdict: Blue Owl Cap In The Eyes Of 13 Experts

Novo Nordisk (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) has outperformed the market over the past 5 years by 11.03% on an annualized basis producing an average annual return of 24.01%. Currently, Novo Nordisk has a market capitalization of $377.67 billion. 
Buying $100 In NVO: If an investor had bought $100 of NVO stock 5 years ago, it would be worth $294.83 today based on a price of $85.03 for NVO at the time of writing.
<h3>Novo Nordisk's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734732019_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In This Stock 5 Years Ago Would Be Worth This Much Today

Nucor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUE#NYSE">NUE</a>) has outperformed the market over the past 5 years by 2.55% on an annualized basis producing an average annual return of 15.52%. Currently, Nucor has a market capitalization of $28.02 billion. 
Buying $100 In NUE: If an investor had bought $100 of NUE stock 5 years ago, it would be worth $205.35 today based on a price of $116.85 for NUE at the time of writing.
<h3>Nucor's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734731107_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Nucor Stock In The Last 5 Years

Xcel Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XELB#NASDAQ">XELB</a>) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.13) by 53.85 percent. This is a 60 percent increase over losses of $(0.15) per share from the same period last year. The company reported quarterly sales of $1.91 million which beat the analyst consensus estimate of $1.72 million by 11.16 percent. This is a 27.49 percent decrease over sales of $2.64 million the same period last year.

XELB

Xcel Brands Q3 Adj $(0.06) Beats $(0.13) Estimate, Sales $1.91M Beat $1.72M Estimate

Xcel Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XELB#NASDAQ">XELB</a>) announced its Q3 earnings on Friday, December 20, 2024 at 04:30 PM.
Here's a breakdown of the earnings report.
<h3>Earnings</h3>
Xcel Brands beat estimated earnings by 54.0%, reporting an EPS of $-0.06 versus an estimate of $-0.13.
Revenue was down $725 thousand from the same period last year.
<h3>Overview of Past Earnings</h3>
During the previous quarter, the company beat on EPS by $0.07, leading to a 2.0% drop share price change the next day.
Here's a look at Xcel Brands's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.08</td>
<td>-0.18</td>
<td>-0.25</td>
<td>-0.16</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.01</td>
<td>-0.09</td>
<td>-0.24</td>
<td>-0.15</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>3.62M</td>
<td>2.20M</td>
<td>2.46M</td>
<td>2.80M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>2.95M</td>
<td>2.18M</td>
<td>2.29M</td>
<td>2.64M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Xcel Brands <a href="https://www.benzinga.com/quote/XELB/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Xcel Brands Earnings Report: Q3 Overview

Atea stock drops as COVID-19 therapy fails in late-stage trial

Analyst Maxwell Skor of Morgan Stanley maintained a Hold rating on Atea Pharmaceuticals (AVIR – Research Report), retaining the price target of $6....

Atea Pharmaceuticals: Hold Rating Amidst Clinical Trial Setbacks and Future HepC Focus

Atea Pharmaceuticals reports Q3 results

Atea Pharmaceuticals files for $500M mixed securities shelf

Atea Pharmaceuticals, Inc. ( ($AVIR) ) has released its Q3 earnings. Here is a breakdown of the information Atea Pharmaceuticals, Inc. presented to...

Atea Pharmaceuticals Advances in HCV Treatment Development

Atea Pharmaceuticals, Inc. (AVIR) Q3 2024 Earnings Call Transcript

Atea Pharmaceuticals (AVIR) announced it presented three poster presentations supporting the combination of bemnifosbuvir and ruzasvir as a potenti...

Atea Pharmaceuticals presents three HCV poster presentations at AASLD

Atea Pharmaceuticals (AVIR) announced that the Company's Phase 2 study of the regimen of bemnifosbuvir, a nucleotide analog polymerase inhibitor, a...

Atea Pharmaceuticals announces results from Phase 2 regimen of bemnifosbuvir

Atea Pharmaceuticals (AVIR) announced that it has engaged Evercore to identify potential opportunities to enhance shareholder value, including the ...

Atea Pharmaceuticals retains financial advisor to explore partnerships

Atea Pharmaceuticals engages Evercore to explore partnerships

Press Releases

Atea Pharmaceuticals Announces Publication of Additional Data Further Highlighting Bemnifosbuvir's Metabolic Activation Pathway

Atea Pharmaceuticals Provides Update on Global Phase 3 SUNRISE-3 Trial Evaluating Bemnifosbuvir for Treatment of COVID-19

Atea Pharmaceuticals to Present New Data Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD's The Liver Meeting 2024

Atea Pharmaceuticals to Host Third Quarter 2024 Financial Results Conference Call on November 7, 2024

Atea Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

Atea Pharmaceuticals Presents Multiple New Datasets Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD's The Liver Meeting 2024

Atea Pharmaceuticals to Present and Provide a Business Update at the 7th Annual Evercore HealthCONx Conference

Atea Pharmaceuticals Announces Positive Results from Phase 2 Study of Bemnifosbuvir and Ruzasvir Regimen for Treatment of Hepatitis C Virus (HCV)

Atea Pharmaceuticals Retains Financial Advisor to Explore Strategic Partnerships

Concerned Shareholder Group Calls for Atea Pharmaceuticals to Appoint a New, Shareholder-Oriented Lead Independent Director to Oversee Strategic Review Process

Comments

Atea Pharmaceuticals

Atea Pharmaceuticals (AVIR) Options

Atea Pharmaceuticals (NASDAQ:AVIR) Stock, Option Chain

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga